Ramaprasad Srinivasan

Ramaprasad Srinivasan, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10 - Hatfield CRC, Room 1-5940
  • Bethesda, MD 20892
  • 240-858-3700
  • 301-480-2869
Urologic Oncology Branch


Dr. Srinivasan is developing precision, targeted treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. Currently, he is investigating a variety of mechanism-based treatment strategies in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer (HLRCC) and hereditary papillary renal cell cancer (HPRC).

Areas of Expertise

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Key Publications

Belzutifan (MK-6482) for von Hippel-Lindau Disease-associated renal cell carcinoma.

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SH, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R.
N Engl J Med. 385: 2036-2046, 2021. [ Journal Article ]

Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.

Pahwa R, Dubhashi J, Singh A, Jailwala P, Lobanov A, Thomas CJ, Ceribelli M, Wilson K, Ricketts CJ, Vocke CD, Wells C, Bottaro DP, Linehan WM, Neckers L, Srinivasan R.
J Exp Clin Cancer Res.. 41(1): 208, 2022. [ Journal Article ]

Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer.

Crooks DR, Maio N, Lang M, Ricketts CJ, Vocke CD, Gurram S, Turan S, Kim YY, Cawthon GM, Sohelian F, De Val N, Pfeiffer RM, Jailwala P, Tandon M, Tran B, Fan TW, Lane AN, Ried T, Wangsa D, Malayeri AA, Merino MJ, Yang Y, Meier JL, Ball MW, Rouault TA, Srinivasan R, Linehan WM.
Sci Signal. 14(664); Jan 5: 2021. [ Journal Article ]

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
J Clin Oncol.. 31(2)/ Jan 10: 181-186, 2013. [ Journal Article ]

Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

Kauffman EC, Lang M, Rais-Bahrami S, Gupta GN, Wei D, Yang Y, Sourbier C, Srinivasan R.
BMC Cancer. 19(1): 917, 2019. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Head Shot Lisa Mac
Physician Associate
Lisa Mac, PA-C, MPH
Maria Zumer
Physician Associate
Maria Zumer, PA-C
Head Shot Wanda Bell-Farrell
Research Nurse
Wanda Bell-Farrell, RN, MS, CCRP
head shot_ Donna Drake
Data Manager (Contr.)
Donna Drake
Head Shot Mabel Cruz
Patient Care Coordinator (Contr)
Mabel Cruz
head shot Sameer Issaq
Sameer Issaq, Ph.D.
Head Shot Roma Pahwa
Research Fellow
Roma Pahwa, Ph.D.